Oncogenic Cell Tagging and Single-Cell Transcriptomics Reveal Cell Type-Specific and Time-Resolved Responses to Vhl

Samvid Kurlekar1,2, Joanna D C C Lima1,2, Ran Li1

  • 1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Cancer Research
|March 19, 2024
PubMed

Insights

Loss of the von Hippel Lindau (VHL) gene initiates kidney cancer by altering specific cell types. This study visualizes and analyzes these early oncogenic events using single-cell sequencing.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Understanding cancer initiation requires defining early oncogenic events and cellular responses.
  • The von Hippel Lindau (VHL) tumor suppressor gene is crucial in clear cell renal cell carcinoma development.

Purpose of the Study:

  • To investigate the cellular and molecular changes following VHL gene loss in the kidney.
  • To identify specific cell types involved in VHL-deficient renal cell carcinoma initiation.
  • To develop a method for tracking and analyzing cells with genetic alterations in their native context.

Main Methods:

  • Longitudinal study of VHL inactivation in kidney cells.
  • Utilized a tdTomato reporter coupled to VHL allele for cell marking.
  • Employed single-cell RNA sequencing to analyze cellular responses.
  • Investigated adaptive changes in renal epithelium and interstitium.

Main Results:

  • VHL inactivation induced cell type-specific responses in the kidney.
  • Identified a proximal tubular cell population with oncogenic potential.
  • Observed heterogeneous cellular effects, including transient proliferation and cell elimination.
  • Revealed adaptive changes in the renal epithelium and interstitium over time.

Conclusions:

  • Early cellular responses to VHL inactivation shape oncogenesis specificity.
  • The developed experimental strategy enables in-situ analysis of oncogenic processes.
  • Findings provide insights into VHL tumor suppressor function and renal cell carcinoma development.
  • Highlights potential therapeutic targets based on cell type-specific responses.